Institutional Ownership
Regeneron Pharmaceuticals
CUSIP 75886F107COMREGNQ1 2026
Latest EPS (Diluted)
$12.23
Q2 2026 · Jun 30, 2026
Latest Revenue
$4.29B
Reported quarter
Latest Net Income
$1.30B
Reported quarter
Quarters on Record
12
From SEC XBRL filings
Quarterly Earnings
EPS, revenue & net income · SEC XBRL (10-Q / 10-K)
| Period | Quarter | EPS (Basic) | EPS (Diluted) | Revenue | Net Income | Form |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Q2 2026 | $12.62 | $12.23 | $4.29B | $1.30B | 10-Q |
| Mar 31, 2026 | Q1 2026 | $6.99 | $6.75 | $3.61B | $727.20M | 10-Q |
| Sep 30, 2025 | Q3 2025 | $14.09 | $13.62 | $3.75B | $1.46B | 10-Q |
| Jun 30, 2025 | Q2 2025 | $13.24 | $12.81 | $3.68B | $1.39B | 10-Q |
| Mar 31, 2025 | Q1 2025 | $7.58 | $7.27 | $3.03B | $808.70M | 10-Q |
| Sep 30, 2024 | Q3 2024 | $12.40 | $11.54 | $3.72B | $1.34B | 10-Q |
| Jun 30, 2024 | Q2 2024 | $13.25 | $12.41 | $3.55B | $1.43B | 10-Q |
| Mar 31, 2024 | Q1 2024 | $6.70 | $6.27 | $3.15B | $722.00M | 10-Q |
| Sep 30, 2023 | Q3 2023 | $9.48 | $8.89 | $3.36B | $1.01B | 10-Q |
| Jun 30, 2023 | Q2 2023 | $9.05 | $8.50 | $3.16B | $968.40M | 10-Q |
| Mar 31, 2023 | Q1 2023 | $7.64 | $7.17 | $3.16B | $817.80M | 10-Q |
| Sep 30, 2022 | Q3 2022 | $12.31 | $11.66 | $2.94B | $1.32B | 10-Q |